CareDx, Inc 8-K, filed Oct 29, 2026

CareDx, Inc. (CDNA)

8-K 2026-10-29 For: 2026-10-29

Added on October 29, 2026

About this 8-K

CareDx, Inc filed this 8-K on October 29, 2026.

CareDx reported third-quarter revenue of $139 million, up 39% year-over-year, and Adjusted EBITDA of $30 million. It raised 2026 revenue guidance to $520 million to $530 million and Adjusted EBITDA guidance to $90 million to $100 million. AI summary

Items reported

Item 2.02: Financial results
Item 7.01: Regulation FD disclosure
Item 9.01: Financial statements and exhibits

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →



Exhibit No.						Description

99.1						Press Release issued by CareDx, Inc., dated October 29, 2026.
104						Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).



		CAREDX, INC.

Date: October 29, 2026	By:	/s/ JOHN HANNA
		John W. Hanna
		President, Chief Executive Officer and Director


	Three Months Ended September 30,
	2026		2025
Revenue:
Testing services revenue	$	119,191	$	72,168
Product revenue	—		12,478
Patient and digital solutions revenue	20,171		15,409
Total revenue	139,362		100,055
Operating expenses:
Cost of testing services	24,683		14,705
Cost of product	—		5,629
Cost of patient and digital solutions	15,604		10,320
Research and development	21,324		16,769
Sales and marketing	31,650		24,449
General and administrative	37,989		28,429


Total operating expenses	131,250		100,301
Income (loss) from operations	8,112		(246)
Other income:
Interest income, net	2,208		2,013

Other income (expense), net	372		(107)
Total other income	2,580		1,906
Income before income taxes	10,692		1,660
Income tax benefit	8,600		15
Net income	$	19,292	$	1,675
Net income per share:
Basic	$	0.37	$	0.03
Diluted	$	0.35	$	0.03
Weighted-average shares used to compute net income (loss) per share:
Basic	52,116,051		52,507,582
Diluted	54,984,989		53,736,790


	As of
	September 30, 2026		December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	250,480	$	65,429
Marketable securities	—		111,779
Accounts receivable	47,730		42,628
Inventory	9,144		26,705
Prepaid and other current assets	13,943		10,591
Total current assets	321,297		257,132
Property and equipment, net	27,011		32,971
Operating lease right-of-use assets	23,541		22,760
Marketable securities, non-current	—		24,165
Intangible assets, net	139,781		31,960
Goodwill	121,709		40,336
Restricted cash	1,410		551
Other assets	6,708		3,353
Total assets	$	641,457	$	413,228
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	10,808	$	9,988
Accrued compensation	40,564		38,107
Accrued and other liabilities	87,603		41,754
Total current liabilities	138,975		89,849
Deferred tax liability	536		181


Contingent consideration, non-current	14,035		161
Operating lease liabilities, less current portion	20,316		19,679
Other liabilities	139		257
Total liabilities	174,001		110,127
Commitments and contingencies
Stockholders’ equity:
Common stock	52		50
Additional paid-in capital	953,558		927,457
Accumulated other comprehensive loss	—		(5,515)
Accumulated deficit	(486,154)		(618,891)
Total stockholders’ equity	467,456		303,101
Total liabilities and stockholders’ equity	$	641,457	$	413,228


	Three Months Ended September 30,
	2026		2025
Cost of testing services reconciliation:
GAAP cost of testing services	$	24,683	$	14,705
Stock-based compensation expense	(213)		(299)
Restructuring costs	—		(120)
Acquisition related-amortization of purchased intangibles	(2,925)		(348)
Non-GAAP cost of testing services	$	21,545	$	13,938
Cost of product reconciliation:
GAAP cost of product	$	—	$	5,629
Stock-based compensation expense	—		(51)
Acquisition related-amortization of purchased intangibles	—		(447)

Restructuring costs	—		(11)
Non-GAAP cost of product	$	—	$	5,120
Cost of patient and digital solutions reconciliation:
GAAP cost of patient and digital solutions	$	15,604	$	10,320
Stock-based compensation expense	(96)		(118)
Acquisition related-amortization of purchased intangibles	(152)		(152)
Restructuring costs	—		8

Non-GAAP cost of patient and digital solutions	$	15,356	$	10,058
Research and development expenses reconciliation:
GAAP research and development expenses	$	21,324	$	16,769
Stock-based compensation expense	(1,197)		(1,146)

Restructuring costs	—		(174)


Non-GAAP research and development expenses	$	20,127	$	15,449
Sales and marketing expenses reconciliation:
GAAP sales and marketing expenses	$	31,650	$	24,449
Stock-based compensation expense	(831)		(1,782)
Acquisition related-amortization of purchased intangibles	(817)		(655)

Transformational initiative costs	—		(183)
Restructuring costs	—		(233)

Non-GAAP sales and marketing expenses	$	30,002	$	21,596
General and administrative expenses reconciliation:
GAAP general and administrative expenses	$	37,989	$	28,429
Business development and portfolio optimization expense*	(5,527)		—
Stock-based compensation expense	(7,318)		(5,022)




Impairment of intangible asset	—		(2,258)

Transformational initiative costs	—		(341)

Non-GAAP general and administrative expenses	$	25,144	$	20,808




Total other income reconciliation:
GAAP other income	$	2,580	$	1,906



Non-GAAP other income	$	2,580	$	1,906
Income tax benefit (expense) reconciliation:
GAAP income tax benefit	$	8,600	$	15
Tax effect related to amortization of purchased intangibles	—		(111)
Non-GAAP income tax benefit (expense)	$	8,600	$	(96)


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


	Three Months Ended
	September 30, 2026			June 30, 2026			September 30, 2025
GAAP total revenue	$	139,362		$	131,948		$	100,055
GAAP cost of sales	40,287			34,966			30,654
GAAP gross profit	99,075			96,982			69,401
GAAP gross margin %	71		%	74		%	69		%
Stock-based compensation expense	309			321			468
Restructuring costs	—			—			123

Business development and portfolio optimization expense*	—			311			—
Acquisition related-amortization of purchased intangibles	3,077			355			947
Non-GAAP gross profit	$	102,461		$	97,969		$	70,939
Non-GAAP gross margin %	74		%	74		%	71		%


	Year Ended December 31, 2025
GAAP net loss	$	(21,354)
Stock-based compensation expense	34,864
Acquisition related-amortization of purchased intangibles	6,349
Acquisition related fees and expenses	204
Change in estimated fair value of contingent consideration	703
Tax effect related to amortization of purchased intangibles	(431)
Impairment of intangible asset	2,258
Transformational initiative costs	2,824
Restructuring costs	890
Litigation settlement expense	5,710
Non-GAAP net income	32,017
Interest income	(9,174)
Income tax expense	702
Depreciation expense	8,667
Other (income) expense, net	(524)
Adjusted EBITDA	$	31,688


	Three Months Ended September 30,
	2026		2025
Net cash provided by operating activities (GAAP)	$	12,718	$	37,358
Less: item not included in free cash flows
Capital expenditures (GAAP)	$	(1,615)	$	(1,305)
Free cash flow (non-GAAP)	$	11,103	$	36,053